Showing results (81-90 of 136) with videos related to

Sort By:
Pageof 14
International Clinical Psychopharmacology|February 25, 2005
Lithium toxicity after switch from fosinopril to lisinoprilJonathan M Meyer, Adrian Dollarhide, In-Lin Tuan
Schizophrenia Research|October 12, 2004
Atypical antipsychotics and glucose dysregulation: a systematic reviewHua Jin, Jonathan M Meyer, Dilip V Jeste
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|June 6, 2002
Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published casesHua Jin, Jonathan M Meyer, Dilip V Jeste
Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists|March 7, 2006
A comprehensive review of behavioral interventions for weight management in schizophreniaCatherine Loh, Jonathan M Meyer, Susan G Leckband
Expert Opinion on Investigational Drugs|September 29, 2009
Lurasidone: a new drug in development for schizophreniaJonathan M Meyer, Antony D Loebel, Edward Schweizer
Psychopharmacology Bulletin|March 26, 2008
Switching from other agents to extended-release carbamazepine in acute maniaRif S El-Mallakh, Terence A Ketter, Richard H Weisler, et al.
Expert Opinion on Drug Metabolism & Toxicology|June 1, 2023
Personalized switching from oral to long-acting injectable second-generation antipsychotics in schizophrenia treatment using pharmacokinetic considerationsGeorgios Schoretsanitis, Jonathan M Meyer, Andreas Conca, et al.
Journal of Psychiatric Practice|November 26, 2009
Antipsychotic prescribing practices following withdrawal of concomitant carbamazepineDanielle K Strack, Susan G Leckband, Jonathan M Meyer
Pageof 14